Metabolic effects of the left atrial appendage exclusion (the heart hormone study)

J Cardiovasc Electrophysiol. 2022 Sep;33(9):2064-2071. doi: 10.1111/jce.15604. Epub 2022 Jul 28.

Abstract

Introduction: The effect of epicardial left atrial appendage (LAA) occlusion therapy on lipid and glucose metabolism in atrial fibrillation (AF) patients over the long-term follow-up are unclear.

Methods: In a single-center prospective observational study, 60 patients with longstanding persistent AF with cardiovascular risk factors had undergone an epicardial exclusion procedure. Anthropometric parameters and glucose, glycated hemoglobin (HbA1c), insulin, leptin, adiponectin, free fatty acids, beta-hydroxybutyrate, and total cholesterol levels were evaluated on fasting at baseline before the procedure and compared with levels at 24 h, 7 days, 1, 3, 6, and 24 months follow the procedure.

Results: The mean age of the patients was 67.5 ± 8.1. Insulin levels significantly increased at 7 days, 1, 3, 6, 12, and 24 months follow-up. The leptin levels showed a significant increase in 6, 12, and 24 months when compared to baseline. Whereas the adiponectin levels showed a significant decrease at 3, 6, 12, and 24 months when compared to baseline levels. In patients with the epicardial procedure, when compared to baseline, glucose, glycated hemoglobin, total cholesterol, and beta-hydroxybutyrate levels did not show any significant changes at baseline and 24 months follow-up.

Conclusion: The epicardial exclusion ligation in AF patients was associated with significant changes in insulin, leptin, and adiponectin over long follow-up.

Keywords: adiponectin; atrial fibrillation; epicardial LAA exclusion; insulin; leptin.

Publication types

  • Observational Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • 3-Hydroxybutyric Acid
  • Adiponectin
  • Atrial Appendage* / surgery
  • Atrial Fibrillation* / complications
  • Atrial Fibrillation* / diagnosis
  • Atrial Fibrillation* / surgery
  • Cholesterol
  • Glucose
  • Glycated Hemoglobin
  • Humans
  • Insulins*
  • Leptin
  • Treatment Outcome

Substances

  • Adiponectin
  • Glycated Hemoglobin A
  • Insulins
  • Leptin
  • Cholesterol
  • Glucose
  • 3-Hydroxybutyric Acid